Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Imaging With 68Ga-DOTA-peptides and Peptide Receptor Radionuclide Therapy With 177Lu-DOTA-peptides of Gastroenteropancreatic Neuroendocrine Tumors: Interest of Intra-arterial Hepatic Infusion in Patients With Dominant Liver Metastases"

NCT04837885 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT04837885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04837885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Imaging With 68Ga-DOTA-peptides and Peptide Receptor Radionuclide Therapy With 177Lu-DOTA-peptides of Gastroenteropancreatic Neuroendocrine Tumors: Interest of Intra-arterial Hepatic Infusion in Patients With Dominant Liver Metastases"
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 2
Overall status
Recruiting
Start date
September 24, 2021
Completion date
March 24, 2027
Enrollment
23 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases, neuroendocrine gastroenteropancreatic tumour, neuroendocrine tumor